LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) shares passed below its 50-day moving average during trading on Monday after the company announced weaker than expected quarterly earnings. The stock has a 50-day moving average of $14.79 and traded as low as $12.75. LogicBio Therapeutics shares last traded at $14.00, with a volume of 674,701 shares trading hands.
The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.25).
LogicBio Therapeutics Stock Performance
The firm has a market capitalization of $640.22 million, a P/E ratio of -19.18 and a beta of 2.11. The stock has a 50-day moving average of $14.79 and a 200 day moving average of $10.37. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
See Also
- Five stocks we like better than LogicBio Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
